OBJECTIVE -Women with prior gestational diabetes mellitus (pGDM) are at increased risk of developing type 2 diabetes and associated vasculopathy. Because increased fat mass and inflammatory processes are angiopathic risk factors, the relationship between insulin sensitivity, parameters of subclinical inflammation, and plasma concentrations of adipocytokines was investigated in pGDM both at 3 months and 12 months after delivery.RESEARCH DESIGN AND METHODS -Insulin sensitivity (through a frequently sampled intravenous glucose tolerance test) and plasma concentrations of ultrasensitive C-reactive protein (CRP), adiponectin, plasminogen activator inhibitor (PAI)-1, tumor necrosis factor-␣, leptin, and interleukin-6 were measured in 89 pGDM (BMI 26.9 Ϯ 0.5 kg/m 2 , age 32 Ϯ 0.5 years) and in 19 women with normal glucose tolerance during pregnancy (NGT) (23.7 Ϯ 0.9 kg/m 2 , 31 Ϯ 1.3 years).RESULTS -pGDM showed lower (P Ͻ 0.0001) plasma adiponectin (6.7 Ϯ 0.2 g/ml) than NGT (9.8 Ϯ 0.6 g/ml) and a decreased (P Ͻ 0.003) insulin sensitivity index (S i ) and disposition index (P Ͻ 0.03), but increased plasma leptin (P Ͻ 0.003), PAI-1 (P Ͻ 0.002), and CRP (P Ͻ 0.03). After adjustment for body fat mass, plasma adiponectin remained lower in pGDM (P Ͻ 0.004) and correlated positively with S i (P Ͻ 0.003) and HDL cholesterol (P Ͻ 0.0001) but negatively with plasma glucose (2-h oral glucose tolerance test [OGTT]) (P Ͻ 0.0001), leptin (P Ͻ 0.01), CRP (P Ͻ 0.007), and PAI-1 (P Ͻ 0.0001). On regression analysis, only HDL cholesterol, postload (2-h OGTT) plasma glucose, and S i remained significant predictors of plasma adiponectin, explaining 42% of its variability. Of note, adiponectin further decreased (P Ͻ 0.05) only in insulin-resistant pGDM despite unchanged body fat content and distribution after a 1-year follow-up.CONCLUSIONS -Lower plasma adiponectin concentrations characterize women with previous GDM independently of the prevailing insulin sensitivity or the degree of obesity and are associated with subclinical inflammation and atherogenic parameters.
Diabetes Care 27:1721-1727, 2004P lasma concentrations of adiponectin, an adipocyte-specific collagenlike molecule, are reduced in patients with obesity, coronary artery disease, and type 2 diabetes (1). Longitudinal studies indicate that a decrease in plasma adiponectin parallels the progression of the metabolic syndrome (2,3). Potentially, this observation suggests a predictive role of adiponectin also in the development of type 2 diabetes and atherosclerosis, where it could relate to insulin sensitivity and atherogenic parameters such as the lipid profile, cytokines, and subclinical inflammation. This concept is supported by low plasma adiponectin concentrations in states of enhanced insulin resistance in rhesus monkeys (4) and humans (5), when low plasma adiponectin precedes the decrease in whole-body insulin sensitivity (6,7). Moreover, adiponectin decreases both the attachment of monocytic THP-1 cells to human aortic endothelial cells and suppresses the secretion of tumo...